Education
About Us
Working with TipRanks
Follow Us
Dexcom (DXCM)
NASDAQ:DXCM
DXCM Stock Chart & Stats
$73.34
$0.53(0.67%)
At close: 4:00 PM EST
$73.34
$0.53(0.67%)
Day’s Range― - ―
52-Week Range$54.11 - $93.25
Previous CloseN/A
Volume488.69K
Average Volume (3M)4.76M
Market Cap
$28.60B
Enterprise Value$29.45B
Total Cash (Recent Filing)$3.32B
Total Debt (Recent Filing)$2.52B
Price to Earnings (P/E)40.8
Beta1.08
Next Earnings
Feb 12, 2026EPS Estimate
0.65Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.61
Shares Outstanding390,016,270
10 Day Avg. Volume6,531,689
30 Day Avg. Volume4,764,088
Financial Highlights & Ratios
PEG Ratio39.32
Price to Book (P/B)14.97
Price to Sales (P/S)7.80
P/FCF Ratio49.89
Enterprise Value/Market Cap1.03
Enterprise Value/Revenue6.52
Enterprise Value/Gross Profit11.05
Enterprise Value/Ebitda24.09
Forecast
1Y Price Target
$85.56Price Target Upside16.66% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering22
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
International Expansion And Product FunnelManagement emphasis on accelerating international expansion and improving Stelo app conversion, together with stronger international revenue performance, could drive higher global user adoption and revenue upside.
Product Innovation And MarginsIntroduction of longer‑wear and next‑generation smaller glucose sensors is expected to improve sensing accuracy, reduce per‑patient costs, and support operating‑margin expansion as adoption grows.
Reimbursement And Medicare Risk MitigationAlignment of channel pricing with government oversight estimates and responsive CMS proposals increases the likelihood of stable Medicare reimbursement for supplies, reducing downside risk from competitive bidding.
Bears Say
Competition And U.S. Growth PressureIntense competition in the Type 2 non‑insulin market and slowing U.S. sales growth create risk to market‑share gains and could limit near‑term revenue expansion.
Guidance And Profitability ConcernsManagement guidance indicating revenue growth below some analyst expectations and lower profit margins than modeled, plus reduced near‑term contribution from Stelo, could temper earnings upside.
Product Reliability And ConfidenceA reliability controversy that undermined patient and provider confidence necessitates a reliability reset and could slow new patient starts and refill behavior until trust is restored.
Dexcom News
DXCM FAQ
What was Dexcom’s price range in the past 12 months?
Dexcom lowest stock price was $54.11 and its highest was $93.25 in the past 12 months.
What is Dexcom’s market cap?
Dexcom’s market cap is $28.60B.
When is Dexcom’s upcoming earnings report date?
Dexcom’s upcoming earnings report date is Feb 12, 2026 which is in 15 days.
How were Dexcom’s earnings last quarter?
Dexcom released its earnings results on Oct 30, 2025. The company reported $0.61 earnings per share for the quarter, beating the consensus estimate of $0.576 by $0.034.
Is Dexcom overvalued?
According to Wall Street analysts Dexcom’s price is currently Undervalued.
Does Dexcom pay dividends?
Dexcom does not currently pay dividends.
What is Dexcom’s EPS estimate?
Dexcom’s EPS estimate is 0.65.
How many shares outstanding does Dexcom have?
Dexcom has 390,016,270 shares outstanding.
What happened to Dexcom’s price movement after its last earnings report?
Dexcom reported an EPS of $0.61 in its last earnings report, beating expectations of $0.576. Following the earnings report the stock price went down -14.633%.
Which hedge fund is a major shareholder of Dexcom?
Currently, no hedge funds are holding shares in DXCM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Dexcom Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$85.56 (16.66% Upside)
$85.56 (16.66% Upside)
Blogger Sentiment
Bullish
DXCM Sentiment 77%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 4.3M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $1.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.4%
Last 30 Days ▲ 4.4%
Last 30 Days ▲ 4.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-16.92%
12-Months-Change
Fundamentals
Return on Equity
30.63%
Trailing 12-Months
Asset Growth
18.04%
Trailing 12-Months
Company Description
Dexcom
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system. The company's products candidature comprises Dexcom G7, a next generation G7 CGM system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was incorporated in 1999 and is headquartered in San Diego, California.
DXCM Company Deck
DXCM Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
DexCom's earnings call highlighted robust revenue growth and strategic product expansions, particularly in type 2 diabetes CGM coverage, and noted the introduction of innovative products like DexCom Smart Basal. However, challenges in gross margin management and quality issues with the G7 sensor deployment were noted. The sentiment is buoyed by positive financial performance and strategic advancements, despite some operational challenges.View all DXCM earnings summariesDXCM Revenue Breakdown
71.65% U.S.
28.35% Outside of the U.S.
DXCM Stock 12 Month Forecast
Average Price Target
$85.56
▲(16.66% Upside)
Technical Analysis
Ownership Overview
0.48% Insiders
26.49% Mutual Funds
0.52% Other Institutional Investors
39.63% Public Companies and Individual Investors